Pazopanib, a multikinase inhibitor (potent action on VEGF 1–3, PGDF, FGFR, and milder action on RET) found to have activity against MTCs in preclinical studies, was studied in a multicentre international phase II trial in patients with advanced progressive MTC (74). Here, RET is linked to medullary thyroid gland carcinoma.